gip glp-1 dual agonist The Sustained Effects of a GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes: Cell Metabolism Effects, working principles and target
Description
10.1111/dom.12165 20 SaikiaM.HolterM
Several studies have relatively short follow-up periods and limited sample sizes, which may constrain the evaluation of long-term efficacy and durability
[PubMed ID: 25164763]
Odds of gastrointestinal events were similar between tirzepatide and GLP-1 RAs, except for diarrhoea with tirzepatide 10 mg (OR 1.51 [95% CI 1.07, 2.15], I 2 0%) (Table 2)
www.nejm.org/doi/full/10.1056/NEJMoa2032183.
Garca-Cceres C, Quarta C, Varela L, Gao Y, Gruber T, Legutko B, et al
